Engineering CAR-T Cells: Design Concepts
Explore this paper's citation graph
Summary
How the principles of TCR recognition, including spatial constraints, Kon/Koff rates, and synapse formation, along with in-depth analysis of CAR signaling might be applied to develop safer and more effective synthetic tumor targeting receptors are discussed.
- Type
- review
- Published
- 2015-07-11
- Cited by
- 447
- References
- 85
- Access
- Open access
- OpenAlex
- https://openalex.org/W1910881826
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:12885952
Keywords
T-cell receptor, Chimeric antigen receptor, Immunological synapse, Receptor, CD28
References
- Agonist/endogenous peptide–MHC heterodimers drive T cell activation and sensitivity
- Designed ankyrin repeat proteins (DARPins) from research to therapy.
- Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses.
- Functional Comparison of Engineered T Cells Carrying a Native TCR versus TCR-like Antibody–Based Chimeric Antigen Receptors Indicates Affinity/Avidity Thresholds
- Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+ T Cells
- The PD-1 Pathway in Tolerance and Autoimmunity
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
- Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
- The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.
- Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor
- Structure of the T-cell antigen receptor: evidence for two CD3 epsilon subunits in the T-cell receptor-CD3 complex.
- Biophysical Mechanism of T Cell Receptor Triggering in a Reconstituted System
- Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells.
- TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
- Dynamic Imaging of T Cell-Dendritic Cell Interactions in Lymph Nodes
- CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.
- Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response.
- Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
- Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.
Cited by
- Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side
- Designed Ankyrin Repeat Proteins as Her2 Targeting Domains in Chimeric Antigen Receptor-Engineered T Cells
- Targeting and suppression of HER3-positive breast cancer by T lymphocytes expressing a heregulin chimeric antigen receptor
- Injectable polypeptide hydrogel for dual-delivery of antigen and TLR3 agonist to modulate dendritic cells in vivo and enhance potent cytotoxic T-lymphocyte response against melanoma.
- Phenotypic models of T cell activation
- Immunotherapy and tumor microenvironment
- Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications
- Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies
- The Plasma Membrane as a Reservoir, Protective Shield, and Light-Triggered Launch Pad for Peptide Therapeutics.
- Metabolic communication in tumors: a new layer of immunoregulation for immune evasion
- Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects
- Quantitative Analyses of Core Promoters Enable Precise Engineering of Regulated Gene Expression in Mammalian Cells
- The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing.
- Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China
- Efficacy and toxicity management of CAR-T-cell immunotherapy: a matter of responsiveness control or tumour-specificity?
- Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model
- Adoptive immunotherapy against ovarian cancer
- Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials
- A Perspective of Immunotherapy for Prostate Cancer
- Changing landscape of immuno-oncology: CAR-T therapy and PD1/PDL1 blockade
Related papers
- CD28 Signals in the Immature Immunological Synapse 1
- TCR dynamics on the surface of living T cells.
- Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells
- CD28 provides T-cell costimulation and enhances PI3K activity at the immune synapse independently of its capacity to interact with the p85/p110 heterodimer.
- The role of endocytic trafficking in antigen T cell receptor activation
- CD28 plays a critical role in the segregation of PKC theta within the immunologic synapse.
- Spatiotemporal regulation of T cell co-stimulation by TCR-CD28 microclusters through PKCθ translocation
- Dynamic regulation of T‐cell costimulation through TCR–CD28 microclusters
- Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength.